Abstract / Summary
Abstract Persistent infection with carcinogenic human papillomavirus (HPV) types causes the great majority of cervical cancers. For more than a decade, randomized trials, surveillance studies, and national registry analyses have demonstrated reductions in vaccine-type HPV infection, high-grade cervical precancer, and invasive cervical cancer following HPV vaccination. Direct evidence regarding cervical cancer mortality has emerged more recently because cohorts vaccinated in early adolescence first had to reach ages at which cervical cancer deaths became observable. A 2026 population-based analysis from England reported no cervical cancer deaths among the most highly vaccinated women aged 20 to 24 years during 2020 to 2024, with substantial mortality reductions also observed in older vaccinated cohorts, although uncertainty increased with age. This narrative review synthesizes the biological and epidemiologic evidence linking HPV vaccination to mortality prevention, critically appraises the England mortality study and its age-stratified findings, considers limitations related to cervical screening and the modeled counterfactual, and discusses implications for cervical cancer elimination, including relevance to Qatar and the wider Eastern Mediterranean region. Current evidence supports early adolescent HPV vaccination as a central cancer-prevention intervention, while continued cervical screening, timely treatment, high and equitable vaccine coverage, and long-term surveillance remain essential. The available mortality evidence is compelling at the population-program level but should not be interpreted as an individual-level randomized estimate of vaccine effectiveness against cervical cancer death.